Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone

Summary 1. Cyclo‐oxygenase (COX)‐2 inhibitors and other non‐steroidal anti‐inflammatory drugs (NSAIDs) have been implicated in increased cardiovascular events. However, the direct effects of these drugs on cardiac function have not been explored extensively. Given the important role of the renin–ang...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental pharmacology & physiology 2010-09, Vol.37 (9), p.912-918
Hauptverfasser:	Wang, Bing H, Bertucci, Micka C, Ma, Jian Yang, Adrahtas, Anastasia, Cheung, Raymond Y, Krum, Henry
Format:	Artikel
Sprache:	eng
Schlagworte:	aldosterone Aldosterone - pharmacology angiotensin II Angiotensin II - pharmacology Animals Animals, Newborn Anti-Inflammatory Agents, Non-Steroidal - pharmacology cardiac fibrosis cardiac hypertrophy Cardiomegaly - pathology Celecoxib Collagen - biosynthesis cyclo-oxygenase 2 inhibitors Cyclooxygenase 2 Inhibitors - pharmacology Female Fibroblasts - drug effects Fibroblasts - metabolism Fibroblasts - pathology Fibrosis Heart - drug effects Hep G2 Cells Hepatocytes - metabolism Humans Lactones - pharmacology Male Myocardium - metabolism Myocardium - pathology Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Myocytes, Cardiac - pathology Naproxen - pharmacology noproxen Pyrazoles - pharmacology Rats Renin-Angiotensin System - physiology rofecoxib Sulfonamides - pharmacology Sulfones - pharmacology Vasoconstrictor Agents - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!